2012 Annual Shareholder Meeting Presentation

1,574 views

Published on

Chairman Lloyd Dean and CEO Chris Calhoun present at the Annual Meeting of Shareholders on August 16, 2012

Published in: Health & Medicine, Business
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
1,574
On SlideShare
0
From Embeds
0
Number of Embeds
563
Actions
Shares
0
Downloads
5
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide

2012 Annual Shareholder Meeting Presentation

  1. 1. Cytori Therapeutics, Inc. Annual Shareholder Meeting August 16, 2012 9:00 AM PT
  2. 2. Safe Harbor StatementThis presentation may contain certain ‘forward-looking statements’. Allstatements, other than statements of historical fact, that address activities, eventsor developments that we intend, expect, project, believe or anticipate will ormay occur in the future are forward-looking statements. Such statements arebased upon certain assumptions and assessments made by our management inlight of their experience and their perception of historical trends, currentconditions, expected future developments and other factors they believe to beappropriate.The forward-looking statements included in this presentation are also subject to anumber of material risks and uncertainties. We caution investors not to placeundue reliance on the forward-looking statements contained in this presentation.We would advise reading our annual report filed with the United States Securitiesand Exchange Commission on Form 10-K for a more detailed description of theserisks.
  3. 3. Our Company Mission To improve the quality and length of life by providing innovative cell therapy products CYTORI - The Leader in Cell Therapy
  4. 4. Lesley’s Story Pre-TreatmentAdjunct to Burn Resurfacing Pre-Treatment
  5. 5. Lesley’s Story Pre-Treatment 3 Weeks Post Treatment 8 Weeks Post Treatment 20 Weeks Post Treatment
  6. 6. Lesley’s Story Pre-Treatment Burn Scar Repair 18 Months Pre-Treatment
  7. 7. Lesley’s Story Pre-Treatment Burn Scar Repair Before 18 Months Pre-Treatment
  8. 8. Lesley’s Story Pre-Treatment 12 Month Post Op 18 Month Post Op
  9. 9. Easy to Access Cells A small amount of fat is removed (about half a can of coke)
  10. 10. Point-of-Care Your tissue is processed right at the side of your bed
  11. 11. About an hour … And available when you need it
  12. 12. The Power of Cell Therapy > 5,000 patients have been treated using their own cells with Cytori products
  13. 13. Clinical Leadership > 5,000 Patients Treated (est.) 1% 2% 5% Breast Recon 1% 11% 5 Clinical Trials • 3 Complete (2 CV, 1 Breast) Breast • 2 Ongoing (2 CV) Augmentation 27% • Others planned Other Fat Grafting Cardiac 40+ Investigator Studies 53% Urology
  14. 14. Cytori Product Families>5,000 patients treated >8,600 patients treatedAvailable in 47 countries Available in 52 countries Available globally
  15. 15. Momentum is Building Expanded soft tissue claims Recurring revenues increasing Preparing for vascular market Demand for cell & tissue banking is increasing
  16. 16. Advance Pipeline toward Market Access Preclinical Research Phase I/II Pivotal Full Market Access Private Pay/ ReimbursementBreast /Buttock Face AugmentationBreast Cancer ReconstructionSoft Tissue Facial WastingDiabetic Foot UlcersFistulaBurnsRadiation Induced InjurySUISports Related InjuryHeart Failure / No Option ChronicMyocardial IschemiaAcute Myocardial InfarctionCritical Limb IschemiaPuregraftBanking
  17. 17. Refractory Heart Failure ATHENA TRIAL • FDA Approved Multicenter Trial • Double Blind, Placebo controlled • 45 Patients: 30 ADRC, 15 Placebo • 6 Leading US Cardiac Cell Therapy Centers Dr. Perin, Dr. Willerson, Texas Heart Dr. Henry, Minneapolis Heart Dr. Miller, University South Florida Dr. Pepine, University of Florida, Gainsville Dr. Mendelsohn, Cardiology PC, Alabama Dr. Schatz, Scripps La Jolla, CaliforniaEmerson Perin, MDTexas Heart Institute
  18. 18. Acute Heart Attack ADVANCE TRIAL • European Pivotal Trial • Prospective • Randomized (2:1) • Double Blind • Placebo controlled • Up to 216 patients for STEMI • Enrollment to begin in Q4 ’12 • G5 • The Netherlands • Canada • PolandEric Duckers, MD, PhDRotterdam, The Netherlands
  19. 19. Intellectual Property • 51 Patents + 2 Allowances • 75+ Applications in process • ~50% growth in portfolio • Avg 1 patent / month
  20. 20. Shareholder Value • Advance pipeline toward Market Access • Manage to cash flow positive  Grow revenue  Control costs • Strengthen balance sheet
  21. 21. Milestones Achieved in 2012FDA approval to initiate ATHENACE Mark for wounds, burns, radiation, ischemiaAdditional country approvals (Russia, Croatia)Breast Reconstruction Reimbursement filing - UKPublish 6 & 18 month data: APOLLOPublish 12 month data: RESTORE 2Puregraft 850 FDA & CE Mark, PG250 approvalsGrow IP Portfolio > 15%
  22. 22. Milestones• Establish Strategic Partnership• Initiate ATHENA Trial – US (First patient enrolled)• Cardiovascular CE Mark expansion• Additional country approvals (Canada, Australia, New Zealand, Japan)• FDA Appeal Resolution• Publish 18 month data – PRECISE Trial• Revenue growth target of $9 million
  23. 23. Vision Cells concentrated from a person’s own fat tissue, will be used to treat a broad array of diseases in patients around the world MISSION: To improve the quality and length of life by providing innovative cell therapy products
  24. 24. Cytori is… Defining the market for point- of-care cell therapy Delivering on the promise in cell therapy Leading in delivering cell therapy to doctors & patients MISSION: To improve the quality and length of life by providing innovative cell therapy products
  25. 25. Thank You !Cytori: Restoring Lives

×